Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
View ORCID ProfileStéphane Le Vu, View ORCID ProfileMarion Bertrand, View ORCID ProfileMarie-Joëlle Jabagi, View ORCID ProfileJérémie Botton, View ORCID ProfileAlain Weill, View ORCID ProfileRosemary Dray-Spira, View ORCID ProfileMahmoud Zureik
doi: https://doi.org/10.1101/2022.07.31.22278064
Stéphane Le Vu
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marion Bertrand
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Marie-Joëlle Jabagi
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Jérémie Botton
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
2Faculté de Pharmacie, Université Paris-Saclay, 92296, Châtenay-Malabry, France
Alain Weill
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Rosemary Dray-Spira
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
Mahmoud Zureik
1EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France
3University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, Montigny le Bretonneux, France
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted August 01, 2022.
Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval
Stéphane Le Vu, Marion Bertrand, Marie-Joëlle Jabagi, Jérémie Botton, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik
medRxiv 2022.07.31.22278064; doi: https://doi.org/10.1101/2022.07.31.22278064
Subject Area
Subject Areas
- Addiction Medicine (329)
- Allergy and Immunology (648)
- Anesthesia (173)
- Cardiovascular Medicine (2484)
- Dermatology (209)
- Emergency Medicine (384)
- Epidemiology (11947)
- Forensic Medicine (10)
- Gastroenterology (714)
- Genetic and Genomic Medicine (3874)
- Geriatric Medicine (358)
- Health Economics (648)
- Health Informatics (2503)
- Health Policy (963)
- Hematology (350)
- HIV/AIDS (812)
- Medical Education (384)
- Medical Ethics (106)
- Nephrology (411)
- Neurology (3638)
- Nursing (204)
- Nutrition (542)
- Oncology (1887)
- Ophthalmology (549)
- Orthopedics (229)
- Otolaryngology (298)
- Pain Medicine (240)
- Palliative Medicine (71)
- Pathology (459)
- Pediatrics (1066)
- Primary Care Research (434)
- Public and Global Health (6305)
- Radiology and Imaging (1335)
- Respiratory Medicine (845)
- Rheumatology (388)
- Sports Medicine (333)
- Surgery (424)
- Toxicology (51)
- Transplantation (179)
- Urology (152)